Table 1.
Baseline patient characteristics for current report and previously reported cases.
Case | Age | Sex | Child-Pugh class, score | ALBIgrade, score | Tumor stage TNM, BCLC | History of MTAtreatment | History of hepaticresection | Etiology | Platelet(×105/μl) | Splenomegaly, splenic index | Reason for discontinuation of AB treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 70 | M | A, 6 | 2, -1.81 | IVB, C | – | – | HCV (SVR) | 4.9 | +, 985 | AE |
2 | 78 | M | A, 6 | 2, -2.01 | III, B | + | + | NASH | 9.4 | -, 391 | AE |
3 | 61 | M | B, 7 | 2, -1.50 | IVB, C | + | + | HCV | 12.0 | +, 793 | AE |
4 | 55 | M | A, 5 | 2, -2.57 | IVB, C | – | – | NASH | 7.7 | +, 1688 | AE |
5 | 69 | M | A, 5 | 2, -2.45 | III, B | – | + | Alcohol | 7.6 | +, 2099 | AE |
6 | 37 | M | A, 6 | 2, -1.67 | IVB, C | + | + | NASH | 7.7 | +, 553 | PD |
7 | 72 | M | A, 6 | 2, -1.94 | III, B | – | – | Alcohol | 6.2 | +, 1136 | – |
Median (range) | 69 (37–78) | -1.94 (-1.67–2.57) | 7.7 (4.9–12.0) | 985 (391–2099) | |||||||
13, Case 1 | 60s | M | A, 5 | 2, -2.78 | IVB, C | + | + | HCV (SVR) | 11.1 | Spleen volume, 193 cm3 | NA |
13, Case 2 | 60s | M | A, 6 | 2, -2.16 | III, B | + | – | HCV (SVR) | 12.6 | Spleen volume, 262 cm3 | NA |
ALBI, albumin-bilirubin index; BCLC, Barcelona Clinic Liver Cancer; MTA, molecular targeted agent; AB, atezolizumab plus bevacizumab; HCV, hepatitis C virus; SVR, sustained virological response; AE, adverse event; NASH, non-alcoholic steatohepatitis; PD, progressive disease; Ref., reference; NA, not available.